FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer

Journal for ImmunoTherapy of Cancer

Volumn 5, Issue 1, 2017, Pages

  Symeonides, Stefan N ^b   Anderton, Stephen M ^a   Serrels, Alan ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Checkpoint blockade; FAK; Immunotherapy; Pancreatic cancer

Indexed keywords

CHECKPOINT KINASE INHIBITOR; CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DEFACTINIB; FOCAL ADHESION KINASE; GEMCITABINE; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; STROMAL CELL DERIVED FACTOR 1; ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE 1; PROTEIN KINASE INHIBITOR;

CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL TRIAL (TOPIC); FIBROBLAST; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NOTE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOTHERAPY; PANCREAS TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; FOCAL ADHESION KINASE 1; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 85013343450     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-017-0217-6     Document Type: Note

References (9)

1. Wolchok JD, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-33.
2. Kunk PR, et al. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer. 2016;4:14.
3. Jiang H, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22(8):851-60.
4. McLean GW, et al. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer. 2005;5(7):505-15.
5. Serrels A, et al. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell. 2015;163(1):160-73.
6. Tavora B, et al. Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature. 2014;514(7520):112-6.
7. Stokes JB, et al. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011;10(11):2135-45.
8. Shapiro IM, et al. Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship. Sci Transl Med. 2014;6(237):237ra68.
9. Lee BY, et al. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015;146:132-49.